Mural Oncology plc (NASDAQ: MURA)’s stock price has gone decline by -5.31 in comparison to its previous close of 3.20, however, the company has experienced a -12.43% decrease in its stock price over the last five trading days. globenewswire.com reported 2024-09-23 that WALTHAM, Mass and DUBLIN, Sept. 23, 2024 (GLOBE NEWSWIRE) — Mural Oncology plc (Nasdaq: MURA), a clinical-stage immuno-oncology company developing novel, investigational engineered cytokine therapies designed to address areas of unmet need for patients with a variety of cancers, today announced the appointment of Sachiyo Minegishi to its board of directors, effective September 20. Ms. Minegishi will serve as Chair of the Audit Committee and will also be joining the company’s Nominating and Corporate Governance Committee.
Is It Worth Investing in Mural Oncology plc (NASDAQ: MURA) Right Now?
Opinions on the stock are mixed, with 1 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for MURA is 15.74M, and at present, short sellers hold a 3.09% of that float. On September 27, 2024, the average trading volume of MURA was 151.36K shares.
MURA’s Market Performance
MURA’s stock has seen a -12.43% decrease for the week, with a -7.90% drop in the past month and a -1.30% fall in the past quarter. The volatility ratio for the week is 6.15%, and the volatility levels for the past 30 days are at 5.84% for Mural Oncology plc The simple moving average for the past 20 days is -6.24% for MURA’s stock, with a -23.38% simple moving average for the past 200 days.
Analysts’ Opinion of MURA
Many brokerage firms have already submitted their reports for MURA stocks, with Rodman & Renshaw repeating the rating for MURA by listing it as a “Buy.” The predicted price for MURA in the upcoming period, according to Rodman & Renshaw is $15 based on the research report published on June 28, 2024 of the current year 2024.
Morgan Stanley, on the other hand, stated in their research note that they expect to see MURA reach a price target of $13. The rating they have provided for MURA stocks is “Overweight” according to the report published on April 04th, 2024.
MURA Trading at -8.01% from the 50-Day Moving Average
After a stumble in the market that brought MURA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -82.18% of loss for the given period.
Volatility was left at 5.84%, however, over the last 30 days, the volatility rate increased by 6.15%, as shares sank -3.81% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -12.93% lower at present.
During the last 5 trading sessions, MURA fell by -12.43%, which changed the moving average for the period of 200-days by -24.06% in comparison to the 20-day moving average, which settled at $3.23. In addition, Mural Oncology plc saw -48.82% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at MURA starting from ALTSCHULLER Susan, who purchase 10,000 shares at the price of $3.21 back on Aug 14 ’24. After this action, ALTSCHULLER Susan now owns 10,000 shares of Mural Oncology plc, valued at $32,071 using the latest closing price.
Keson-Brookes Maiken, the of Mural Oncology plc, sale 2,157 shares at $3.41 during a trade that took place back on Jul 18 ’24, which means that Keson-Brookes Maiken is holding 43,850 shares at $7,355 based on the most recent closing price.
Stock Fundamentals for MURA
Current profitability levels for the company are sitting at:
- -66.13 for the present operating margin
- -0.2 for the gross margin
The net margin for Mural Oncology plc stands at -66.19. The total capital return value is set at -0.82.
Based on Mural Oncology plc (MURA), the company’s capital structure generated 0.05 points at debt to capital in total, while cash flow to debt ratio is standing at -14.43.
Currently, EBITDA for the company is -192.07 million with net debt to EBITDA at 0.65. When we switch over and look at the enterprise to sales, we see a ratio of -22.49. The receivables turnover for the company is 2.6for trailing twelve months and the total asset turnover is 0.01. The liquidity ratio also appears to be rather interesting for investors as it stands at 8.65.
Conclusion
To sum up, Mural Oncology plc (MURA) has seen a bad performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
